Clinical Trial Update: Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial evaluating mycophenolate mofetil for nephrotic syndrome in children after rituximab treatment has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Frequent Relapsing Nephrotic Syndrome
• Nephrotic Syndrome
• Steroid-dependent Nephrotic Syndrome

Drugs mentioned

• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)

Snippet

Sponsor: Children's Hospital of Fudan University | Conditions: Frequently Relapsing Nephrotic Syndrome, Steroid-Dependent Nephrotic Syndrome | Phase 3 | Status: WITHDRAWN